Bridgewater, New Jersey, March 18, 2016 – Asana BioSciences, LLC today announced that Dr. Drew Rasco of South Texas Accelerated Research Therapeutics, San Antonio, Texas, will present an update on ASN002, which the company is developing for non-Hodgkin lymphoma, at the 14th International Congress on Targeted Anticancer Therapies being held on March 21-23, 2016 in Washington, D.C. Dr. Rasco is the principal investigator of the ongoing clinical trial of ASN002. The presentation details are as follows:
Title: A Phase I/II and PK/PD Study of ASN002, a Potent Dual SYK/JAK Inhibitor, in Patients with Advanced Solid Tumors and B-Cell Lymphomas
Speaker: Drew Rasco, M.D., South Texas Accelerated Research Therapeutics
Session Date/Time: Plenary Session 3, Monday, March 21, 2016, 1:15 PM
ASN002 is a potent inhibitor of both SYK kinase and the JAK kinase family. SYK and JAK are tyrosine kinases involved in cytokine production and signaling. ASN002 demonstrated robust activity in a number of preclinical models of lymphoma and hematologic malignancies, including an ibrutinibresistant lymphoma (DLBCL) cell line. ASN002 is currently under evaluation in a Phase I/II study in patients with solid tumors and lymphomas. The Phase II portion of the study will further evaluate safety, tolerability and efficacy in patients with diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma. The study is ongoing, and dose escalation continues after assessment of the first three cohorts, which have shown good tolerability and safety.
Asana will also present preclinical data on its product candidate ASN003, a potent and highly selective inhibitor of BRAF and PI3K pathway kinases. The presentation details are as follows:
Title: ASN003, A Highly Selective Inhibitor of BRAF and PI3K Kinases Shows
Strong Antitumor Activity in Melanoma and Colon Cancer Xenograft Models
Presenter: Sanjeeva Reddy, Ph.D., Asana BioSciences
Session Date: Poster Session 3, Monday, March 21, 2016
ASN003 has broader anti-proliferative activity in tumor cell lines as compared to the BRAF selective inhibitors, vemurafenib and dabrafenib, and shows robust antitumor activity in multiple tumor xenograft models. Dual targeting of the BRAF and PI3K pathways with ASN003 has the potential to overcome and/or delay acquired resistance to selective BRAF inhibition, and may also result in improved activity in cancers driven by both pathways relative to selective BRAF inhibitors or selective PI3K pathway inhibitors alone. First-in-human trials with ASN003 are being planned.
About Asana BioSciences, LLCAsana BioSciences, LLC, an independent member of the Amneal alliance of companies, is a research and development company based in Bridgewater, New Jersey, specializing in the of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Aother lead molecule ASN001 (CYP17 inhibitor for prostate cancer) is currently in Phase I/II clinical studies in the United States. development. www.asanabiosciences.com
Roger Smith, Ph.D.